

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/007916

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K38/22 A61P3/10 A61P3/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C07K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, EMBASE, BIOSIS, Sequence Search

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02/10436 A (BAAK JAN ; BRIGHAM & WOMENS HOSPITAL (US)) 7 February 2002 (2002-02-07) cited in the application claims 1-46 sequences 27,78	1-18, 20-25, 35,36
X	WO 00/21986 A (INCYTE PHARMA INC ; KLINGLER TOD M (US); VOLKMUTH WAYNE (US); WALKER M) 20 April 2000 (2000-04-20) cited in the application page 2, line 13 claims 1-12	1-18, 20-25, 35,36

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the International filing date but later than the priority date claimed

- *T* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the International search

11 January 2005

Date of mailing of the International search report

22 04. 2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hars, J

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2004/007916

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-25, 31-36 (partially); 26-30 (entirely)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-36 (partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

BEST AVAILABLE COPY

Continuation of Box II.2

Claims Nos.: 1-25,31-36 (partially); 26-30 (entirely)

Present claims 1-36 relate to compounds/compositions/methods defined by reference to a desirable characteristic or property, namely:

- a) "a DG008" <-> "a mammalian DG008"
- b) "an effector/modulator of "
- c) "metabolic diseases or dysfunctions for controlling the function of a gene and/or a gene product which is influenced and/or modified by a DG008"
- d) "binding target/agent"
- e) "a reference activity"
- f) "(poly)peptide identified"
- g) "diseases or dysfunctions"

The claims cover all compounds/compositions/methods having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds/compositions/methods. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compounds/compositions/methods by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds/compositions/methods:

- a) only human DG008 as specified in SEQ IDs 1 and 2
- b) nothing
- c), g) only pancreatic diseases (e.g. diabetes), obesity, metabolic syndrome, modulation of pancreatic development or regeneration of pancreatic cells or tissues
- d), e), f) nothing

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

overcome.

BEST AVAILABLE COPY

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-36 (partially)

First and second medical use / diagnostic use of DG008 (SEQ IDs 1,2; nucleic acids, proteins, vectors, cells, etc.) against pancreatic diseases (e.g. diabetes), obesity and metabolic syndrome.

2. claims: 1-36 (partially)

First and second medical use / diagnostic use of DG065 (SEQ IDs 3,4; nucleic acids, proteins, vectors, cells, etc.) against pancreatic diseases (e.g. diabetes), obesity and metabolic syndrome.

3. claims: 1-36 (partially)

First and second medical use / diagnostic use of DG210 (SEQ IDs 5,6; nucleic acids, proteins, vectors, cells, etc.) against pancreatic diseases (e.g. diabetes), obesity and metabolic syndrome.

4. claims: 1-36 (partially)

First and second medical use / diagnostic use of DG239 (SEQ IDs 7,8; nucleic acids, proteins, vectors, cells, etc.) against pancreatic diseases (e.g. diabetes), obesity and metabolic syndrome.

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/007916

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0210436	A	07-02-2002	WO 0210436 A2	07-02-2002
			US 6703204 B1	09-03-2004
<hr/>				
WO 0021986	A	20-04-2000	AU 6417799 A	01-05-2000
			CA 2314004 A1	20-04-2000
			EP 1037915 A1	27-09-2000
			JP 2002527054 T	27-08-2002
			WO 0021986 A2	20-04-2000
			US 2002019000 A1	14-02-2002
<hr/>				

BEST AVAILABLE COPY